YAP-mediated DDX3X confers resistance to ferroptosis in breast cancer cells by reducing lipid peroxidation

被引:0
|
作者
Dai, Jia-Zih [1 ,2 ]
Hsu, Wen-Jing [1 ,2 ]
Lin, Mei-Hsiang [3 ]
Shueng, Pei-Wei [4 ,5 ]
Lee, Chi-Ching [6 ,7 ]
Yang, Ching-Chieh [8 ,9 ,10 ]
Lin, Cheng-Wei [1 ,2 ,11 ]
机构
[1] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan
[2] Taipei Med Univ, Coll Med, Sch Med, Dept Biochem & Mol Cell Biol, 250 Wu Xing St, Taipei 11031, Taiwan
[3] Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, Taipei, Taiwan
[4] Far Eastern Mem Hosp, Dept Radiol, Div Radiat Oncol, New Taipei City, Taiwan
[5] Natl Yang Ming Chiao Tung Univ, Coll Med, Sch Med, Taipei, Taiwan
[6] Istanbul Sabahattin Zaim Univ, Fac Engn & Nat Sci, Dept Food Engn, Istanbul, Turkiye
[7] Klaipeda State Univ Appl Sci, Fac Technol, Dept Food Technol & Nutr, Klaipeda, Lithuania
[8] Chi Mei Med Ctr, Dept Radiat Oncol, Tainan 710, Taiwan
[9] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan
[10] Natl Sun Yat Sen Univ, Coll Med, Sch Med, Kaohsiung, Taiwan
[11] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan
关键词
Ferroptosis; DEAD-box helicase 3 X -linked; Glutathione peroxidase 4; Yes-associated protein; Breast cancer; GLUTATHIONE-S-TRANSFERASES; RNA HELICASE DDX3; COLORECTAL-CANCER; SENSITIVITY; MOLECULE; TARGET; DEATH;
D O I
10.1016/j.freeradbiomed.2025.03.019
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolic shifts in cancer cells were found to participate in tumorigenesis, especially driving chemotherapeutic resistance. Ferroptosis is a newly discovered form of cell death induced by excessive accumulations of iron and lipid peroxidation. Susceptibility to ferroptosis can be intrinsically regulated by various cellular metabolic pathways. Therefore, inducing ferroptosis might be a promising anticancer therapeutic strategy. DEAD-box helicase 3 X-linked (DDX3X), a critical modulator of RNA metabolism, was identified as an oncogene in breast cancer and also participates in cancer metabolism and chemotherapeutic resistance. However, the molecular regulation of the association between DDX3X and ferroptosis is largely unknown. Herein, we investigated the correlation between resistance to ferroptosis and DDX3X expression in breast cancer cells. We found that elevation of DDX3X was associated with increased resistance to a ferroptosis inducer in breast cancer cells, and manipulating DDX3X expression regulated the sensitivity to the ferroptosis inducer. Importantly, DDX3X upregulated expression of the anti-ferroptotic enzyme glutathione peroxidase 4 (GPX4) gene to confer ferroptosis resistance in breast cancer cells. Moreover, DDX3X was transcriptionally upregulated by the yes-associated protein (YAP). Knockdown of YAP downregulated DDX3X mRNA expression and facilitated lipid peroxidation, but that were restored in the presence of DDX3X. Clinically, coexpression of DDX3X and YAP was found in a variety of malignancy, and their elevation conferred poor survival prognosis in patients with breast cancer. Together, our findings reveal the crucial role of DDX3X in sensitivity to ferroptosis and underscore its potential as a diagnostic marker and therapeutic target. DDX3X renders resistance to ferroptosis and plays a role in mitigating lipid peroxidation, paving the way for therapeutic vulnerability via targeting cancer metabolism.
引用
收藏
页码:330 / 339
页数:10
相关论文
共 50 条
  • [31] Ferroptosis mediated inhibition of breast cancer cells by (3-elemene incorporated GSH/pH dual responsive nanomicelles
    Shen, Sihan
    Xie, Ran
    Wang, Yiqun
    Jia, Lingyu
    Zhu, Zhangran
    Ma, Hai
    Wang, Lifang
    Sui, Feng
    Zhao, Yu
    Zhao, Qinghe
    Chen, Yanjun
    EUROPEAN POLYMER JOURNAL, 2025, 223
  • [32] TBK1 and GSK3 mediated TRAF2 phosphorylation confers resistance to PI3K-AKT inhibition in breast cancer cells
    Habelhah, Hasem
    Zhang, Laiqun
    CANCER RESEARCH, 2024, 84 (06)
  • [33] The YAP1/SIX2 axis is required for DDX3-mediated tumor aggressiveness and cetuximab resistance in KRAS-wild-type colorectal cancer
    Wu, De-Wei
    Lin, Po-Lin
    Wang, Lee
    Huang, Chi-Chou
    Lee, Huei
    THERANOSTICS, 2017, 7 (05): : 1114 - 1132
  • [34] crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
    Zou, Yutian
    Yang, Anli
    Chen, Bo
    Deng, Xinpei
    Xie, Jindong
    Dai, Danian
    Zhang, Jinhui
    Tang, Hailin
    Wu, Tao
    Zhou, Zhigang
    Xie, Xiaoming
    Wang, Jin
    DRUG RESISTANCE UPDATES, 2024, 77
  • [35] A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells
    J A Vendrell
    S Ghayad
    S Ben-Larbi
    C Dumontet
    N Mechti
    P A Cohen
    Oncogene, 2007, 26 : 4656 - 4667
  • [36] ErbB3 is required for erbB2-mediated paclitaxel resistance in breast cancer cells
    Wang, Shuiliang
    Gao, Lizhi
    Huang, Xiaoping
    Liu, Bolin
    CANCER RESEARCH, 2009, 69
  • [37] A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells
    Vendrell, J. A.
    Ghayad, S.
    Ben-Larbi, S.
    Dumontet, C.
    Mechti, N.
    Cohen, P. A.
    ONCOGENE, 2007, 26 (32) : 4656 - 4667
  • [38] Effective targeting of breast cancer by the inhibition of P-glycoprotein mediated removal of toxic lipid peroxidation byproducts from drug tolerant persister cells
    Szebenyi, Kornelia
    Furedi, Andras
    Bajtai, Eszter
    Sama, Sai Nagender
    Csiszar, Agnes
    Gombos, Balazs
    Szabo, Pal
    Grusch, Michael
    Szakacs, Gergely
    DRUG RESISTANCE UPDATES, 2023, 71
  • [39] ETV4-mediated transcriptional activation of SLC12A5 exacerbates ferroptosis resistance and glucose metabolism reprogramming in breast cancer cells
    Wang, Huan
    Dai, Yanyan
    Wang, Fengxiang
    MOLECULAR MEDICINE REPORTS, 2024, 30 (06)
  • [40] Persistent activation of Stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells
    Gritsko, T
    Williams, A
    Turkson, J
    Kaneko, S
    Bowman, T
    Huang, M
    Nam, S
    Eweis, I
    Diaz, N
    Sullivan, D
    Yoder, S
    Enkemann, S
    Eschrich, S
    Lee, JH
    Beam, CA
    Cheng, J
    Minton, S
    Muro-Cacho, CA
    Jove, R
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 11 - 19